

 PROCEDURES FOR PRIOR AUTHORIZATION

Completed forms can be faxed in confidence to 1-514-286-8480 for residents of Quebec and 1-844-661-2640 for residents of all other provinces

Upon receipt, this request will be confidentially reviewed according to payment criteria developed by Medavie Blue Cross in consultation with independent health care consultants. In some cases, additional clinical or diagnostic information may be required to process your claim.

For Quebec residents, the criteria for prior authorization are adjusted to meet the requirements of the Régie de l'assurance maladie du Québec (RAMQ).

- Prior Authorization is a pre-approval process to determine if certain products will be reimbursed under a member's benefit plan.
- Please complete entire form. Incomplete forms cannot be processed.
- **For certain medications, approval for reimbursement may be conditional on confirmation of enrollment in the patient support program.**
- Prior Authorization may be limited to a specified period or quantity of medication. Some Medavie Blue Cross plans may require you to purchase a drug requiring prior authorization from a preferred pharmacy*. If your prior authorization request is approved, a case manager may contact you, your physician, or Patient Assistance Program to provide information about the program and to arrange to have your prescription transferred to the preferred pharmacy.
**Not applicable in Quebec.*
- In cases where a request for Prior Authorization is declined, Medavie Blue Cross is denying payment for a product and is not challenging the medical opinion of the physician nor rendering a medical opinion.
- Any costs associated with the completion of this form or obtainment of additional medical information are the responsibility of the member.
- Renewal of the Prior Authorization will be considered by Medavie Blue Cross upon request from the patient/member. The renewal request should include information from the physician supporting continued use of the medication.
- Prior Authorization coverage is contingent on your continued status as a Medavie Blue Cross cardholder or beneficiary.
- If this is a request under the *Mesure du patient d'exception* for a Quebec resident, please include a completed *Patient d'exception* form that can be found here: www.medaviebc.ca/en/resources, in addition to this document.
- If you would like more information about our Patient First Network, including how your Patient Support Program can become integrated with our new enhanced Prior Authorization processes, please send an e-mail to: patientfirstnetwork@medavie.bluecross.ca.

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480

1 PHARMACY INFORMATION

This section is to be completed by the Professional coordinating the request on behalf of the member (PSP, Cancer Care Navigator or Pharmacy)

Decision communication preference: ☐ Fax, Number: _____ ☐ Telephone, Number: _____

Name of Program/Pharmacy: _____

Contact Name: _____ Contact E-mail: _____

2 PATIENT INFORMATION

Part A

Patient Name: _____ Date of Birth: _____
(mm/dd/yyyy)

E-mail address of patient (or of legal guardian if patient is underage): _____

Address: _____ Suite: _____ City: _____

Province: _____ Postal Code: _____ Telephone Number: _____

Policy Number: _____ ID Number: _____

Do you have valid Medicare coverage in your current province of residence? ☐ Yes ☐ No

Have you already purchased this prescription? ☐ Yes ☐ No

Please attach your paid-in-full receipt with this request form. If you have already submitted your receipt to Medavie Blue Cross, please indicate the date of the oldest receipt. Date: _____
(mm/dd/yyyy)

Part B – Coordination of Benefits

Do you or any dependant have coverage for this drug under any other plan or program? ☐ Yes ☐ No If Yes, complete the following:

Policy Number: _____ Carrier: _____
(If applicable, please attach Explanation of Benefits from prior carrier with complete form)

If the patient is a dependent, provide the birth day and month of the cardholder for the other carrier: _____
(mm/dd)

Public-Funded Program – Have you applied for coverage through a public-funded program? ☐ Yes ☐ No

If No, please indicate why: _____

Part C – Authorization

I understand that the personal information I have provided herein is collected and used by Medavie Blue Cross to administer the terms of my policy or the group policy of which I am an eligible member, recommend suitable products and services that I am eligible for as a member of a policy, and other applicable purposes, as described in the Medavie Blue Cross Privacy Statement at www.medaviebc.ca.

Depending on the type of coverage I carry, limited personal information such as claim, health and/or financial related data may be collected from and/or released to following third parties as required for the purposes of administering and managing the benefits outlined in the policy of which I am an eligible member. These third parties may include healthcare providers, other insurance companies, regulatory authorities and investigative bodies, services providers, and/or the cardholder of any contract under which I am a participant.

Where allowed by law, my information may be shared with Medavie Blue Cross employees or service providers in jurisdictions other than where it was collected. If I am a resident of Quebec, this includes transferring or disclosing my personal information to Medavie Blue Cross employees or service providers outside of that province.

I understand that my consent is only valid for the time it is needed to achieve the purposes outlined herein, unless I withdraw it. I understand I may withdraw my consent at any time. However, in some instances doing so may prevent Medavie Blue Cross from providing me with certain products or services that may be useful to me and/or my dependents. This consent complies with federal and provincial privacy laws.

For more details about our information practices, including how your personal information is protected, how to access or correct personal information, or if you have concerns or questions, please see our Medavie Blue Cross Privacy Statement available at www.medaviebc.ca or call 1-800-667-4511.

Signature of Patient: _____

Date: _____
(mm/dd/yyyy)

Residents of All Other Provinces
PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec
PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480



3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____
 Policy Number: _____ ID Number: _____
 E-mail address of patient or of legal guardian if patient is underage: _____

3A Patient Support Program (PSP) Enrollment

Is patient enrolled in the Patient Support Program? ☐ No ☐ Yes, specify Program ID #: _____

Indicate the name of the Patient Support Program: _____

PSP phone #: _____ PSP Fax #: _____

Product Name	Strength	Dosage	Diagnosis
CRYSVITA (BUROSUMAB)			

Patient weight: _____ ☐ lbs ☐ kg Date of diagnosis: _____
 (mm/dd/yyyy)

Expected duration of treatment: _____ Indicate if the disease or injury is work related: ☐ Yes ☐ No

Was treatment initiated in hospital? ☐ Yes ☐ No Where is the drug administered? _____

Indicate the specialty of the physician who initiated or recommended the treatment: _____

Is the patient currently on, or previously been on this drug? ☐ Yes ☐ No

↳ If yes, indicate the treatment start date: _____
 (mm/dd/yyyy)

↳ And coverage provided by: _____
 (if not Medavie Blue Cross, please provide a pharmacy receipt showing purchase of this drug)

For Initial Request, please complete sections 3B and 3D. For Renewals, please complete sections 3C and 3D.

3B Initial Request

Please list all the drugs that were previously tried, or could not be tried because of contraindications. The information for the following drug categories (relative to each diagnosis) must be provided, including details on the contraindication if applicable.

- X-linked hypophosphatemia: active vitamin D, oral phosphate
- Tumor-induced osteomalacia: active vitamin D, oral phosphate

Product Name	Dosage	Start Date (mm/dd/yyyy)	End Date (mm/dd/yyyy)	Response to Treatment or Contraindication

Is the drug being prescribed according to the Health Canada product monograph? ☐ Yes ☐ No

*NOTE: Do not provide genetic test results.

Approved indications from Health Canada:

1. X-linked hypophosphatemia**Pediatric and adult patients**

PHEX gene mutation*:

☐ Present in the patient

☐ Present in a directly related family member with appropriate X-linked inheritance

↳ Plasma fibroblast growth factor 23 (FGF23) level:

☐ Higher than normal

☐ Other. Specify: _____

☐ Absence of PHEX gene mutation

☐ Other. Specify: _____

*NOTE: Do not provide genetic test results.

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____
 Policy Number: _____ ID Number: _____
 E-mail address of patient or of legal guardian if patient is underage: _____

3B Initial Request (cont'd)**1. X-linked hypophosphatemia (cont'd)****Pediatric patients**

Rickets severity score (RSS) at the time Crysivita treatment is initiated: ☐ < 2 points ☐ ≥ 2 points

Growth plates: ☐ Fused ☐ Unfused

Does the patient have fasting hypophosphatemia? ☐ Yes ☐ No

Does the patient have normal renal function? ☐ Yes ☐ No

↳ Fasting serum creatinine levels: _____ ☐ μmol/L ☐ mg/dL

Adult patients

Fasting serum phosphorus: _____ mmol/L TmP/GFR: _____ mg/dL

Serum intact FGF23 (iFGF23) level by Kainos assay: _____ pg/ml

Estimated glomerular filtration rate (GFR): _____ ml/min

↳ If the patient suffers from renal insufficiency, is it due to nephrocalcinosis? ☐ Yes ☐ No ☐ Not applicable

Does the patient have classic clinical features? ☐ Yes ☐ No

↳ If yes, specify: ☐ Short stature ☐ Bowed legs ☐ Other. Specify: _____

Is there skeletal pain attributable to XLH and/or osteomalacia? ☐ Yes ☐ No

Has the patient tried conventional therapy (active vitamin D and oral phosphate supplementation)? ☐ Yes ☐ No

↳ If yes, specify the following:

Is there presence of either radiographic evidence of osteomalacia, non-healing complete fractures or non-healing incomplete fractures following this treatment? ☐ Yes ☐ No

Has there been development of hyperparathyroidism or nephrocalcinosis? ☐ Yes ☐ No

2. Tumor-induced osteomalacia

Fasting serum phosphorus: _____ mmol/L TmP/GFR: _____ mg/dL

Corrected serum calcium: _____ mg/dL

Serum intact FGF23 (iFGF23) level by Kainos assay: _____ pg/ml

Estimated glomerular filtration rate (GFR): _____ ml/min

↳ If the patient suffers from renal insufficiency, is it due to nephrocalcinosis? ☐ Yes ☐ No ☐ Not applicable

Is the tumor amenable to cure by surgical excision of the underlying tumor/lesion? ☐ Yes ☐ No

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____
Policy Number: _____ ID Number: _____
E-mail address of patient or of legal guardian if patient is underage: _____

3B Initial Request (cont'd)

2. Tumor-induced osteomalacia (cont'd)

Has the patient tried conventional therapy (active vitamin D and oral phosphate supplementation)? ☐ Yes ☐ No
↳ If yes, specify the following:
Has there been improvement in osteomalacia following this treatment? ☐ Yes ☐ No
Has there been development of hyperparathyroidism or nephrocalcinosis? ☐ Yes ☐ No

3C Renewal Request

Please provide information on the evolution of the disease to evaluate the response to treatment.

Date of initial evaluation (pretreatment): _____ (mm/dd/yyyy)
Date of most recent evaluation: _____ (mm/dd/yyyy)

1. X-linked hypophosphatemia

Pediatric and adult patients

While on treatment with Crysvita, the following condition has developed or progressed:

- Hyperparathyroidism: ☐ Yes ☐ No
- Nephrocalcinosis: ☐ Yes ☐ No
- Evidence of fracture or pseudo-fracture based on radiographic assessment: ☐ Yes ☐ No
- Fasting hypophosphatemia: ☐ Yes ☐ No

Growth plates: ☐ Fused ☐ Unfused

Pediatric patients

	Initial result (pretreatment)	Result after the first 12 months of treatment	Most recent result
RSS total score:			

Has there been an improvement of at least one point on the Radiographic Global Impression of Change (RGI-C) scale compared to the radiographs preceding the start of treatment? ☐ Yes ☐ No

3 SPECIALTY DRUG INFORMATION

Name of patient: _____ Date of Birth: _____
Policy Number: _____ ID Number: _____
E-mail address of patient or of legal guardian if patient is underage: _____

3C Renewal Request (cont'd)

2. Tumor-induced osteomalacia

While on treatment with Crysvisa, the following condition has developed or progressed:

- Hyperparathyroidism: ☐ Yes ☐ No
- Nephrocalcinosis: ☐ Yes ☐ No
- Evidence of fracture or pseudo-fracture based on radiographic assessment: ☐ Yes ☐ No
- Fasting hypophosphatemia: ☐ Yes ☐ No

3D Additional Information

Please indicate any additional information pertaining to this request.

i HEALTH PROFESSIONAL STATEMENT

I certify that I have reviewed all pages of this request and that all information provided is true, correct and complete.

First Name: _____ Last Name: _____ Permit Number: _____

Specialty: _____

Clinic Name: _____

Address: _____ Suite: _____

City: _____ Province: _____ Postal Code: _____

E-mail: _____ Telephone: _____ Fax: _____

Signature: _____ Date: _____

(mm/dd/yyyy)

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit.

Residents of All Other Provinces

PO BOX 220, MONCTON (NB) E1C 8L3
TEL.: 1-800-667-4511 FAX: 1-844-661-2640

Residents of Quebec

PO BOX 3300, STATION B, MONTREAL (QC) H3B 4Y5
TEL.: 1-888-588-1212 FAX: 1-514-286-8480